Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNK | O75909 | 1/20 | 0.40 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 3/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | THRA | P10827 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21769475 | 0.93 | THRA (0.42) | THRATHRB | |
| SCHEMBL21769497 | 0.89 | CCNK (0.43) | CCNKCDK12CYP1A2CYP3A4GAA | |
| SCHEMBL21769237 | 0.85 | CCNK (0.44) | CCNKCDK12GAA | |
| SCHEMBL21769489 | 0.85 | RBP4 (0.41) | CYP1A2CYP3A4GAACYP2D6CYP2C9 | |
| SCHEMBL21769252 | 0.85 | TSHR (0.42) | CYP1A2CYP3A4GAACYP2D6CYP2C9 | |
| SCHEMBL21769486 | 0.83 | KDM4E (0.43) | CYP1A2GAACYP2C9CYP2C19 | |
| SCHEMBL21769481 | 0.82 | THRA (0.42) | HRH3THRATHRB | |
| SCHEMBL21769506 | 0.81 | RBP4 (0.41) | CYP1A2CYP3A4GAACYP2D6CYP2C9 | |
| SCHEMBL21769407 | 0.81 | TSHR (0.41) | CYP1A2CYP3A4GAACYP2D6CYP2C9 | |
| SCHEMBL21769235 | 0.79 | NPSR1 (0.47) | CYP1A2GAACYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200064334-A1 | Dock Derived Compound against Laminin Receptor (37 LR) and Uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200064334-A1 | Dock Derived Compound against Laminin Receptor (37 LR) and Uses thereof | ILK, LRRC47, RPL37 | CCNK 3426/4885CDK12 726/4885CYP1A2 4271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.